Biotech · Private company
Stealth BioTherapeutics Inc.
Track this companyFree. Adds Stealth BioTherapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials183 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- elamipretidePhase 3 · Primary Mitochondrial MyopathyClinicalTrials.gov · fetched Nov 12, 2026
- ElamipretidePhase 3 · Mitochondrial MyopathiesClinicalTrials.gov · fetched Nov 12, 2026
- ElamipretidePhase 3 · Barth SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- ElamipretidePhase 3 · Age Related Macular Degeneration (ARMD)ClinicalTrials.gov · fetched Nov 12, 2026
- elamipretide open label treatmentPhase 3 · Primary Mitochondrial MyopathyClinicalTrials.gov · fetched Nov 12, 2026
- BendaviaPhase 2 · Renal Artery ObstructionClinicalTrials.gov · fetched Nov 12, 2026
- Bendavia (MTP-131)Phase 2 · Reperfusion InjuryClinicalTrials.gov · fetched Nov 12, 2026
- elamipretidePhase 2 · Primary Mitochondrial DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ElamipretidePhase 2 · Skeletal Muscle Mitochondrial Dysfunction in the ElderlyClinicalTrials.gov · fetched Nov 12, 2026
- elamipretide (high dose)Phase 2 · Mitochondrial MyopathyClinicalTrials.gov · fetched Nov 12, 2026
- elamipretide (intermediate dose)Phase 2 · Mitochondrial MyopathyClinicalTrials.gov · fetched Nov 12, 2026
- elamipretide (low dose)Phase 2 · Mitochondrial MyopathyClinicalTrials.gov · fetched Nov 12, 2026
- elamipretide (MTP-131) 1% topical ophthalmic solutionPhase 2 · Leber's Hereditary Optic NeuropathyClinicalTrials.gov · fetched Nov 12, 2026
- Part A Elamipretide 1.0% Ophthalmic SolutionPhase 2 · Fuchs' Corneal Endothelial Dystrophy (FCED)ClinicalTrials.gov · fetched Nov 12, 2026
- Part B Elamipretide 3.0% Ophthalmic SolutionPhase 2 · Fuchs' Corneal Endothelial Dystrophy (FCED)ClinicalTrials.gov · fetched Nov 12, 2026
- Subcutaneous elamipretide through the elamipretide delivery systemPhase 2 · Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle topical ophthalmic solutionPhase 2 · Leber's Hereditary Optic NeuropathyClinicalTrials.gov · fetched Nov 12, 2026
- ElamipretidePhase 1 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials18
- Clinical Trial in Patients With Barth Syndrome- 4TAZPowerPHASE4 · RECRUITING · started Jul 2, 2026ClinicalTrials.gov NCT07531251 · fetched Nov 12, 2026
- Study of Healthy Aging and Physical Function With ElamipretidePHASE2 · RECRUITING · started Nov 26, 2025ClinicalTrials.gov NCT07275424 · fetched Nov 12, 2026
- ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)PHASE3 · ACTIVE_NOT_RECRUITING · started May 30, 2024ClinicalTrials.gov NCT06373731 · fetched Nov 12, 2026
- Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)PHASE3 · COMPLETED · started Apr 29, 2022ClinicalTrials.gov NCT05162768 · fetched Nov 12, 2026
- FRDA Investigator Initiated Study (IIS) With ElamipretidePHASE1_PHASE2 · COMPLETED · started Mar 3, 2022ClinicalTrials.gov NCT05168774 · fetched Nov 12, 2026
- ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GAPHASE2 · COMPLETED · started Mar 27, 2019ClinicalTrials.gov NCT03891875 · fetched Nov 12, 2026
- A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label ExtensionPHASE3 · TERMINATED · started Oct 9, 2017ClinicalTrials.gov NCT03323749 · fetched Nov 12, 2026
- A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth SyndromePHASE2_PHASE3 · COMPLETED · started Jul 5, 2017ClinicalTrials.gov NCT03098797 · fetched Nov 12, 2026
- An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)COMPLETED · started Feb 13, 2017ClinicalTrials.gov NCT03048617 · fetched Nov 12, 2026
- Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)PHASE2 · TERMINATED · started Dec 1, 2016ClinicalTrials.gov NCT02976038 · fetched Nov 12, 2026
- An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular DegenerationPHASE1 · COMPLETED · started Oct 28, 2016ClinicalTrials.gov NCT02848313 · fetched Nov 12, 2026
- Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER StudyPHASE2 · COMPLETED · started Aug 22, 2016ClinicalTrials.gov NCT02805790 · fetched Nov 12, 2026
- A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic NeuropathyPHASE2 · COMPLETED · started Mar 1, 2016ClinicalTrials.gov NCT02693119 · fetched Nov 12, 2026
- A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)PHASE1_PHASE2 · COMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02653391 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial MyopathyPHASE1_PHASE2 · COMPLETED · started Feb 1, 2015ClinicalTrials.gov NCT02367014 · fetched Nov 12, 2026
- A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in ElderlyPHASE2 · COMPLETED · started Jan 15, 2015ClinicalTrials.gov NCT02245620 · fetched Nov 12, 2026
- Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal ArteryPHASE1_PHASE2 · TERMINATED · started Dec 1, 2012ClinicalTrials.gov NCT01755858 · fetched Nov 12, 2026
- Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary EventsPHASE2 · COMPLETED · started Apr 1, 2012ClinicalTrials.gov NCT01572909 · fetched Nov 12, 2026